Peter Gottlieb
Concepts (606)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 148 | 2026 | 3890 | 6.650 |
Why?
| | Insulin | 53 | 2026 | 2507 | 2.590 |
Why?
| | C-Peptide | 33 | 2026 | 189 | 2.040 |
Why?
| | Islets of Langerhans | 25 | 2026 | 833 | 1.920 |
Why?
| | Autoantibodies | 40 | 2026 | 1501 | 1.810 |
Why?
| | Hypoglycemic Agents | 23 | 2026 | 1387 | 1.590 |
Why?
| | Insulin-Secreting Cells | 18 | 2021 | 388 | 1.510 |
Why?
| | B-Lymphocytes | 10 | 2025 | 876 | 1.110 |
Why?
| | T-Lymphocytes | 25 | 2025 | 1982 | 0.960 |
Why?
| | Antilymphocyte Serum | 8 | 2021 | 61 | 0.950 |
Why?
| | Antibodies, Monoclonal, Humanized | 14 | 2026 | 985 | 0.940 |
Why?
| | CD4-Positive T-Lymphocytes | 14 | 2025 | 1129 | 0.920 |
Why?
| | Autoantigens | 15 | 2021 | 429 | 0.910 |
Why?
| | Monitoring, Ambulatory | 4 | 2010 | 88 | 0.900 |
Why?
| | Blood Glucose | 18 | 2026 | 2327 | 0.900 |
Why?
| | Autoimmunity | 19 | 2023 | 926 | 0.850 |
Why?
| | Proinsulin | 7 | 2024 | 51 | 0.760 |
Why?
| | Prediabetic State | 8 | 2026 | 245 | 0.750 |
Why?
| | Immunosuppressive Agents | 9 | 2023 | 846 | 0.750 |
Why?
| | Clinical Trials as Topic | 12 | 2025 | 1053 | 0.730 |
Why?
| | Adolescent | 79 | 2026 | 22428 | 0.690 |
Why?
| | Immunotherapy | 6 | 2025 | 653 | 0.650 |
Why?
| | Adult | 96 | 2026 | 40449 | 0.640 |
Why?
| | Addison Disease | 8 | 2012 | 38 | 0.640 |
Why?
| | Child | 72 | 2026 | 22633 | 0.630 |
Why?
| | Blood Glucose Self-Monitoring | 4 | 2010 | 699 | 0.630 |
Why?
| | Humans | 169 | 2026 | 144759 | 0.630 |
Why?
| | CD4 Antigens | 2 | 2013 | 139 | 0.600 |
Why?
| | Immunologic Factors | 7 | 2019 | 255 | 0.600 |
Why?
| | Preventive Medicine | 2 | 2018 | 39 | 0.580 |
Why?
| | Young Adult | 51 | 2026 | 14105 | 0.570 |
Why?
| | Polyendocrinopathies, Autoimmune | 3 | 2010 | 18 | 0.570 |
Why?
| | Diabetes Mellitus, Type 2 | 6 | 2020 | 2583 | 0.550 |
Why?
| | Peptide Fragments | 13 | 2024 | 699 | 0.530 |
Why?
| | Insulin Antibodies | 6 | 2022 | 103 | 0.520 |
Why?
| | CD8-Positive T-Lymphocytes | 10 | 2019 | 917 | 0.500 |
Why?
| | Granulocyte Colony-Stimulating Factor | 6 | 2021 | 89 | 0.500 |
Why?
| | HLA-DQ Antigens | 11 | 2019 | 173 | 0.500 |
Why?
| | Mycophenolic Acid | 3 | 2012 | 120 | 0.470 |
Why?
| | Female | 98 | 2026 | 78271 | 0.450 |
Why?
| | Male | 90 | 2026 | 72315 | 0.450 |
Why?
| | Chromogranin A | 2 | 2024 | 43 | 0.450 |
Why?
| | Peptides | 5 | 2024 | 995 | 0.440 |
Why?
| | Steroid 21-Hydroxylase | 5 | 2012 | 27 | 0.440 |
Why?
| | Monocytes | 4 | 2016 | 538 | 0.440 |
Why?
| | Autoimmune Diseases | 10 | 2017 | 463 | 0.430 |
Why?
| | Immunoglobulin G | 6 | 2018 | 893 | 0.430 |
Why?
| | Glutamate Decarboxylase | 9 | 2022 | 165 | 0.420 |
Why?
| | Mice, Inbred NOD | 16 | 2023 | 610 | 0.420 |
Why?
| | Cytokines | 9 | 2018 | 2061 | 0.410 |
Why?
| | Biomarkers | 13 | 2024 | 4271 | 0.410 |
Why?
| | Vaccines, DNA | 1 | 2013 | 31 | 0.400 |
Why?
| | Cystic Fibrosis | 3 | 2012 | 1158 | 0.380 |
Why?
| | Myeloid Cells | 1 | 2014 | 148 | 0.380 |
Why?
| | alpha 1-Antitrypsin | 1 | 2014 | 102 | 0.380 |
Why?
| | Disease Progression | 17 | 2026 | 2847 | 0.380 |
Why?
| | T-Lymphocyte Subsets | 8 | 2018 | 415 | 0.380 |
Why?
| | Interferon-gamma | 6 | 2021 | 784 | 0.380 |
Why?
| | Immunomodulation | 1 | 2013 | 101 | 0.370 |
Why?
| | Immunologic Memory | 7 | 2019 | 366 | 0.370 |
Why?
| | Genetic Predisposition to Disease | 11 | 2026 | 2363 | 0.340 |
Why?
| | Hypoglycemia | 6 | 2009 | 477 | 0.340 |
Why?
| | Dendritic Cells | 2 | 2014 | 499 | 0.330 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 338 | 0.330 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 4 | 2021 | 54 | 0.320 |
Why?
| | Diabetes Mellitus | 2 | 2023 | 1098 | 0.310 |
Why?
| | Histocompatibility Antigens Class I | 6 | 2011 | 202 | 0.300 |
Why?
| | CD3 Complex | 5 | 2019 | 111 | 0.300 |
Why?
| | Zinc Transporter 8 | 5 | 2026 | 70 | 0.300 |
Why?
| | Immunoconjugates | 4 | 2014 | 132 | 0.300 |
Why?
| | HLA-DR3 Antigen | 5 | 2022 | 76 | 0.300 |
Why?
| | Age of Onset | 7 | 2026 | 551 | 0.300 |
Why?
| | Lymphocyte Activation | 7 | 2025 | 1126 | 0.300 |
Why?
| | HLA-DR Antigens | 8 | 2018 | 220 | 0.290 |
Why?
| | Area Under Curve | 9 | 2024 | 330 | 0.290 |
Why?
| | Glucose Tolerance Test | 7 | 2026 | 361 | 0.280 |
Why?
| | Antibodies, Monoclonal | 6 | 2010 | 1519 | 0.280 |
Why?
| | Clonal Anergy | 3 | 2018 | 54 | 0.270 |
Why?
| | Insulin, Regular, Human | 3 | 2024 | 47 | 0.270 |
Why?
| | Cation Transport Proteins | 3 | 2017 | 118 | 0.260 |
Why?
| | Hearing Aids | 2 | 2021 | 93 | 0.260 |
Why?
| | Toll-Like Receptors | 3 | 2014 | 194 | 0.250 |
Why?
| | Tympanic Membrane | 2 | 2017 | 21 | 0.240 |
Why?
| | Double-Blind Method | 12 | 2021 | 2029 | 0.240 |
Why?
| | Regeneration | 2 | 2017 | 197 | 0.230 |
Why?
| | Receptors, Interleukin-2 | 2 | 2006 | 64 | 0.230 |
Why?
| | Middle Aged | 38 | 2026 | 35875 | 0.230 |
Why?
| | Animals | 34 | 2024 | 38058 | 0.230 |
Why?
| | Haplotypes | 7 | 2026 | 490 | 0.230 |
Why?
| | Time Factors | 10 | 2020 | 7173 | 0.230 |
Why?
| | Child, Preschool | 22 | 2026 | 11787 | 0.220 |
Why?
| | Polymorphism, Single Nucleotide | 5 | 2026 | 2145 | 0.220 |
Why?
| | Protein Precursors | 3 | 2016 | 137 | 0.220 |
Why?
| | Antigen Presentation | 3 | 2018 | 205 | 0.220 |
Why?
| | Insulin, Isophane | 1 | 2004 | 22 | 0.220 |
Why?
| | Administration, Oral | 3 | 2026 | 847 | 0.210 |
Why?
| | T-Lymphocytes, Regulatory | 6 | 2023 | 389 | 0.210 |
Why?
| | Software | 2 | 2008 | 690 | 0.200 |
Why?
| | Mice | 26 | 2024 | 18339 | 0.200 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 3 | 2013 | 97 | 0.200 |
Why?
| | Precision Medicine | 3 | 2023 | 457 | 0.200 |
Why?
| | Temporal Bone | 2 | 2021 | 45 | 0.200 |
Why?
| | Treatment Outcome | 13 | 2026 | 11679 | 0.200 |
Why?
| | Pregnancy in Diabetics | 2 | 2003 | 121 | 0.200 |
Why?
| | Immunotherapy, Active | 2 | 2014 | 9 | 0.190 |
Why?
| | Plasmids | 4 | 2013 | 379 | 0.190 |
Why?
| | Diabetic Ketoacidosis | 2 | 2024 | 210 | 0.190 |
Why?
| | Polyethylene Glycols | 3 | 2018 | 654 | 0.190 |
Why?
| | Histocompatibility Testing | 4 | 2013 | 121 | 0.190 |
Why?
| | Interleukin-1beta | 3 | 2014 | 395 | 0.180 |
Why?
| | Epitopes, T-Lymphocyte | 4 | 2011 | 175 | 0.180 |
Why?
| | Islets of Langerhans Transplantation | 2 | 2015 | 67 | 0.180 |
Why?
| | Lymphocyte Depletion | 2 | 2013 | 132 | 0.180 |
Why?
| | Body Weight | 2 | 2025 | 976 | 0.180 |
Why?
| | Receptors, Antigen, T-Cell | 5 | 2022 | 668 | 0.180 |
Why?
| | Immune Tolerance | 2 | 2017 | 379 | 0.180 |
Why?
| | Methyldopa | 2 | 2019 | 6 | 0.180 |
Why?
| | Recombinant Fusion Proteins | 2 | 2015 | 675 | 0.170 |
Why?
| | Round Window, Ear | 1 | 2021 | 18 | 0.170 |
Why?
| | Imatinib Mesylate | 1 | 2021 | 77 | 0.170 |
Why?
| | Necrobiosis Lipoidica | 1 | 2001 | 2 | 0.170 |
Why?
| | Asymptomatic Diseases | 1 | 2021 | 102 | 0.170 |
Why?
| | Hyperglycemia | 1 | 2024 | 375 | 0.160 |
Why?
| | Histocompatibility Antigens Class II | 3 | 2011 | 364 | 0.160 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2019 | 2027 | 0.160 |
Why?
| | Platelet-Derived Growth Factor | 1 | 2001 | 90 | 0.160 |
Why?
| | History, 21st Century | 2 | 2018 | 219 | 0.160 |
Why?
| | Genotype | 7 | 2026 | 1833 | 0.160 |
Why?
| | History, 20th Century | 2 | 2018 | 325 | 0.160 |
Why?
| | Interleukin-7 Receptor alpha Subunit | 1 | 2019 | 11 | 0.160 |
Why?
| | Biomarkers, Pharmacological | 1 | 2020 | 26 | 0.160 |
Why?
| | Acoustic Stimulation | 1 | 2021 | 333 | 0.160 |
Why?
| | Biological Variation, Population | 1 | 2019 | 20 | 0.150 |
Why?
| | Cytomegalovirus | 2 | 2018 | 168 | 0.150 |
Why?
| | Th2 Cells | 2 | 2014 | 171 | 0.150 |
Why?
| | Hepatitis Delta Virus | 3 | 1994 | 7 | 0.150 |
Why?
| | Graves Disease | 2 | 2017 | 30 | 0.150 |
Why?
| | Epitopes | 5 | 2024 | 485 | 0.150 |
Why?
| | Luminescence | 2 | 2016 | 39 | 0.150 |
Why?
| | Glucagon-Like Peptides | 1 | 2020 | 70 | 0.150 |
Why?
| | Forkhead Transcription Factors | 3 | 2016 | 202 | 0.140 |
Why?
| | Gastrointestinal Microbiome | 2 | 2018 | 771 | 0.140 |
Why?
| | Mass Screening | 2 | 2025 | 1347 | 0.140 |
Why?
| | Cytoprotection | 1 | 2018 | 55 | 0.140 |
Why?
| | Family | 3 | 2025 | 679 | 0.140 |
Why?
| | Viral Proteins | 3 | 1997 | 355 | 0.140 |
Why?
| | Homicide | 2 | 1990 | 68 | 0.140 |
Why?
| | Risk Factors | 14 | 2026 | 10779 | 0.140 |
Why?
| | Immunity, Cellular | 2 | 2018 | 272 | 0.140 |
Why?
| | Twins, Dizygotic | 1 | 2018 | 109 | 0.140 |
Why?
| | Thyroiditis, Autoimmune | 1 | 2017 | 15 | 0.140 |
Why?
| | HLA-A2 Antigen | 1 | 2017 | 35 | 0.130 |
Why?
| | Diabetes Mellitus, Experimental | 2 | 1990 | 198 | 0.130 |
Why?
| | Biomedical Research | 2 | 2018 | 710 | 0.130 |
Why?
| | Twins, Monozygotic | 1 | 2018 | 134 | 0.130 |
Why?
| | Abatacept | 5 | 2023 | 56 | 0.130 |
Why?
| | Hearing Loss | 1 | 2021 | 247 | 0.130 |
Why?
| | HLA Antigens | 5 | 2026 | 225 | 0.130 |
Why?
| | HLA-DR4 Antigen | 4 | 2022 | 74 | 0.130 |
Why?
| | Antibody-Producing Cells | 1 | 2017 | 29 | 0.130 |
Why?
| | Thyroid Gland | 1 | 2017 | 88 | 0.130 |
Why?
| | Treatment Failure | 1 | 2018 | 365 | 0.130 |
Why?
| | Heparin-binding EGF-like Growth Factor | 1 | 2017 | 16 | 0.130 |
Why?
| | Cell Separation | 2 | 2017 | 307 | 0.130 |
Why?
| | Th1 Cells | 2 | 2009 | 139 | 0.130 |
Why?
| | Magnetic Fields | 1 | 2017 | 24 | 0.130 |
Why?
| | Tympanic Membrane Perforation | 1 | 2017 | 17 | 0.130 |
Why?
| | Follow-Up Studies | 9 | 2021 | 5408 | 0.130 |
Why?
| | Inflammation | 4 | 2018 | 2878 | 0.130 |
Why?
| | Dysbiosis | 1 | 2018 | 187 | 0.120 |
Why?
| | Antibody Formation | 1 | 2018 | 294 | 0.120 |
Why?
| | Cytomegalovirus Infections | 1 | 2018 | 206 | 0.120 |
Why?
| | Influenza, Human | 1 | 2022 | 616 | 0.120 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2025 | 1720 | 0.120 |
Why?
| | Trans-Activators | 1 | 1998 | 405 | 0.120 |
Why?
| | RNA, Catalytic | 2 | 1994 | 189 | 0.120 |
Why?
| | Trypanosoma cruzi | 1 | 1995 | 39 | 0.110 |
Why?
| | Photochemotherapy | 1 | 1995 | 39 | 0.110 |
Why?
| | RNA, Viral | 5 | 1992 | 688 | 0.110 |
Why?
| | Host-Pathogen Interactions | 1 | 2018 | 371 | 0.110 |
Why?
| | Tuftsin | 3 | 1983 | 4 | 0.110 |
Why?
| | Dermatologic Agents | 1 | 2015 | 68 | 0.110 |
Why?
| | Protein Kinase Inhibitors | 1 | 2021 | 969 | 0.110 |
Why?
| | Drug Therapy, Combination | 3 | 2018 | 1047 | 0.110 |
Why?
| | Homeodomain Proteins | 1 | 1998 | 523 | 0.110 |
Why?
| | Genes, Viral | 4 | 1992 | 90 | 0.110 |
Why?
| | Cross-Sectional Studies | 7 | 2025 | 5868 | 0.110 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 3 | 2022 | 331 | 0.100 |
Why?
| | RNA, Double-Stranded | 3 | 1990 | 56 | 0.100 |
Why?
| | Cochlear Implants | 1 | 2015 | 95 | 0.100 |
Why?
| | Phenotype | 2 | 2019 | 3162 | 0.100 |
Why?
| | Graft Rejection | 2 | 2015 | 540 | 0.100 |
Why?
| | Crime | 1 | 2014 | 60 | 0.100 |
Why?
| | Criminals | 1 | 2014 | 33 | 0.100 |
Why?
| | Law Enforcement | 1 | 2014 | 48 | 0.100 |
Why?
| | Nanoparticles | 2 | 2017 | 519 | 0.100 |
Why?
| | Withholding Treatment | 1 | 2013 | 80 | 0.100 |
Why?
| | Primary Cell Culture | 1 | 2013 | 173 | 0.100 |
Why?
| | Transglutaminases | 1 | 2013 | 159 | 0.100 |
Why?
| | Cytotoxicity, Immunologic | 2 | 2013 | 223 | 0.090 |
Why?
| | Gene Expression | 2 | 2013 | 1490 | 0.090 |
Why?
| | DNA, Viral | 2 | 1994 | 358 | 0.090 |
Why?
| | Polymorphism, Genetic | 4 | 2010 | 612 | 0.090 |
Why?
| | Adjuvants, Immunologic | 1 | 2014 | 245 | 0.090 |
Why?
| | Amino Acid Sequence | 10 | 2015 | 2155 | 0.090 |
Why?
| | Nucleic Acid Conformation | 3 | 1994 | 726 | 0.090 |
Why?
| | Adaptive Immunity | 1 | 2013 | 169 | 0.090 |
Why?
| | Reproducibility of Results | 3 | 2009 | 3409 | 0.090 |
Why?
| | Communicable Diseases | 1 | 2014 | 163 | 0.090 |
Why?
| | Receptors, Immunologic | 2 | 1983 | 206 | 0.090 |
Why?
| | Pancreatectomy | 1 | 2015 | 285 | 0.090 |
Why?
| | Sensitivity and Specificity | 2 | 2009 | 1985 | 0.090 |
Why?
| | Diabetic Angiopathies | 2 | 2010 | 263 | 0.090 |
Why?
| | Molecular Sequence Data | 11 | 2015 | 2930 | 0.090 |
Why?
| | RNA Phages | 2 | 1988 | 2 | 0.090 |
Why?
| | Flow Cytometry | 4 | 2019 | 1173 | 0.090 |
Why?
| | Down-Regulation | 1 | 2014 | 627 | 0.090 |
Why?
| | Thyroiditis | 1 | 1991 | 4 | 0.090 |
Why?
| | Alleles | 5 | 2011 | 879 | 0.090 |
Why?
| | Proportional Hazards Models | 3 | 2021 | 1325 | 0.090 |
Why?
| | Herpesviridae Infections | 1 | 2012 | 150 | 0.090 |
Why?
| | Cells, Cultured | 7 | 2017 | 4154 | 0.080 |
Why?
| | Lymphocyte Count | 3 | 2019 | 164 | 0.080 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2012 | 101 | 0.080 |
Why?
| | Recombinant Proteins | 3 | 2018 | 1370 | 0.080 |
Why?
| | HLA-B Antigens | 1 | 2011 | 56 | 0.080 |
Why?
| | Organophosphorus Compounds | 1 | 2011 | 85 | 0.080 |
Why?
| | Interleukin-6 | 2 | 2012 | 780 | 0.080 |
Why?
| | Endocrine Cells | 1 | 2010 | 6 | 0.080 |
Why?
| | Cryopreservation | 1 | 2011 | 110 | 0.080 |
Why?
| | Prognosis | 5 | 2021 | 4282 | 0.080 |
Why?
| | Glycine | 1 | 2011 | 187 | 0.080 |
Why?
| | Transplantation Immunology | 1 | 1990 | 29 | 0.080 |
Why?
| | Insulin, Long-Acting | 3 | 2004 | 65 | 0.080 |
Why?
| | Pilot Projects | 3 | 2021 | 1886 | 0.080 |
Why?
| | Drug Delivery Systems | 1 | 2013 | 380 | 0.080 |
Why?
| | Inflammation Mediators | 2 | 2010 | 509 | 0.080 |
Why?
| | Bacteriophages | 2 | 1990 | 111 | 0.080 |
Why?
| | Insulin Glargine | 3 | 2004 | 88 | 0.080 |
Why?
| | Herpesvirus 4, Human | 2 | 2026 | 176 | 0.080 |
Why?
| | Muromonab-CD3 | 1 | 2009 | 6 | 0.080 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 4 | 2014 | 851 | 0.080 |
Why?
| | T-Lymphocytes, Cytotoxic | 2 | 2009 | 177 | 0.070 |
Why?
| | Adrenocorticotropic Hormone | 2 | 2012 | 147 | 0.070 |
Why?
| | Single-Cell Analysis | 2 | 2025 | 358 | 0.070 |
Why?
| | Antigens | 3 | 2023 | 347 | 0.070 |
Why?
| | Receptors, Chemokine | 2 | 2007 | 47 | 0.070 |
Why?
| | Interleukin-17 | 1 | 2009 | 118 | 0.070 |
Why?
| | Calcinosis | 1 | 2010 | 234 | 0.070 |
Why?
| | Vitamin D Deficiency | 1 | 2010 | 186 | 0.070 |
Why?
| | Immunodominant Epitopes | 2 | 2006 | 27 | 0.070 |
Why?
| | Bacteria | 1 | 2015 | 889 | 0.070 |
Why?
| | Mental Health Services | 1 | 2014 | 473 | 0.070 |
Why?
| | Remission Induction | 2 | 2018 | 307 | 0.070 |
Why?
| | Platelet Membrane Glycoprotein IIb | 1 | 2007 | 5 | 0.070 |
Why?
| | Prisoners | 1 | 1990 | 143 | 0.070 |
Why?
| | Enzyme-Linked Immunospot Assay | 3 | 2011 | 37 | 0.070 |
Why?
| | Hydrocortisone | 2 | 2012 | 304 | 0.070 |
Why?
| | Regression Analysis | 1 | 2010 | 1003 | 0.070 |
Why?
| | Insulin Infusion Systems | 2 | 2004 | 477 | 0.060 |
Why?
| | Mental Disorders | 2 | 2014 | 1168 | 0.060 |
Why?
| | Equipment Design | 1 | 2009 | 530 | 0.060 |
Why?
| | Radioimmunoassay | 2 | 2017 | 165 | 0.060 |
Why?
| | Denmark | 3 | 2014 | 50 | 0.060 |
Why?
| | Safety | 1 | 2009 | 356 | 0.060 |
Why?
| | Case-Control Studies | 5 | 2016 | 3604 | 0.060 |
Why?
| | CD40 Antigens | 1 | 2007 | 90 | 0.060 |
Why?
| | Risk Assessment | 3 | 2025 | 3671 | 0.060 |
Why?
| | Microsatellite Repeats | 2 | 2009 | 157 | 0.060 |
Why?
| | Rituximab | 3 | 2013 | 209 | 0.060 |
Why?
| | Receptors, Interleukin-7 | 1 | 2006 | 28 | 0.060 |
Why?
| | Killer Cells, Natural | 2 | 2016 | 467 | 0.060 |
Why?
| | Atherosclerosis | 1 | 2010 | 409 | 0.060 |
Why?
| | Disease Models, Animal | 2 | 2009 | 4557 | 0.060 |
Why?
| | Age Factors | 4 | 2017 | 3333 | 0.060 |
Why?
| | CD4 Lymphocyte Count | 3 | 2015 | 277 | 0.060 |
Why?
| | Mutation | 5 | 2015 | 4089 | 0.060 |
Why?
| | Hybridomas | 2 | 2004 | 234 | 0.060 |
Why?
| | Prospective Studies | 5 | 2026 | 7990 | 0.060 |
Why?
| | Base Sequence | 8 | 1994 | 2190 | 0.060 |
Why?
| | Isoenzymes | 2 | 2004 | 299 | 0.060 |
Why?
| | Proteins | 2 | 2018 | 1021 | 0.060 |
Why?
| | Disease Susceptibility | 2 | 2019 | 348 | 0.060 |
Why?
| | Infant | 5 | 2024 | 10034 | 0.060 |
Why?
| | Diabetic Retinopathy | 2 | 2005 | 208 | 0.060 |
Why?
| | Gene Frequency | 3 | 2016 | 481 | 0.060 |
Why?
| | Protein Tyrosine Phosphatases | 2 | 2004 | 167 | 0.060 |
Why?
| | Chemokines, CXC | 1 | 2005 | 68 | 0.060 |
Why?
| | Risk | 3 | 2019 | 911 | 0.050 |
Why?
| | Signal Transduction | 3 | 2019 | 5226 | 0.050 |
Why?
| | Acetamides | 1 | 2005 | 37 | 0.050 |
Why?
| | Major Histocompatibility Complex | 2 | 2002 | 229 | 0.050 |
Why?
| | Urban Population | 1 | 1988 | 491 | 0.050 |
Why?
| | Prevalence | 3 | 2024 | 2834 | 0.050 |
Why?
| | Exanthema | 2 | 2019 | 84 | 0.050 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2025 | 134 | 0.050 |
Why?
| | Capsid | 3 | 1990 | 94 | 0.050 |
Why?
| | Blood Coagulation Factors | 1 | 1984 | 55 | 0.050 |
Why?
| | Immunophenotyping | 2 | 2018 | 322 | 0.050 |
Why?
| | Coronary Artery Disease | 1 | 2010 | 741 | 0.050 |
Why?
| | Immunoglobulin Fragments | 1 | 1983 | 11 | 0.050 |
Why?
| | Feces | 2 | 2018 | 513 | 0.050 |
Why?
| | Niacinamide | 1 | 2004 | 86 | 0.050 |
Why?
| | Genes, MHC Class II | 2 | 2002 | 76 | 0.050 |
Why?
| | Placebos | 2 | 2013 | 192 | 0.050 |
Why?
| | Leukocytes, Mononuclear | 2 | 2019 | 573 | 0.050 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2005 | 381 | 0.050 |
Why?
| | Immunoassay | 1 | 2003 | 109 | 0.050 |
Why?
| | Genetic Association Studies | 1 | 2025 | 372 | 0.050 |
Why?
| | Cell Survival | 2 | 2019 | 1098 | 0.050 |
Why?
| | Interleukin-4 | 2 | 2002 | 206 | 0.050 |
Why?
| | Tissue Donors | 1 | 2006 | 424 | 0.050 |
Why?
| | Aged | 8 | 2026 | 25913 | 0.050 |
Why?
| | Antigens, CD1 | 1 | 2002 | 60 | 0.050 |
Why?
| | Retrospective Studies | 5 | 2026 | 17066 | 0.050 |
Why?
| | Siblings | 2 | 2018 | 195 | 0.050 |
Why?
| | Mice, Knockout | 1 | 2009 | 3121 | 0.050 |
Why?
| | Receptors, CXCR3 | 2 | 2016 | 17 | 0.050 |
Why?
| | Antibody Affinity | 2 | 2016 | 60 | 0.040 |
Why?
| | Cloning, Molecular | 3 | 2014 | 540 | 0.040 |
Why?
| | Diseases in Twins | 2 | 2018 | 115 | 0.040 |
Why?
| | Cell Differentiation | 1 | 2009 | 2050 | 0.040 |
Why?
| | Canada | 2 | 2014 | 428 | 0.040 |
Why?
| | Cell Proliferation | 2 | 2009 | 2496 | 0.040 |
Why?
| | Preconception Care | 1 | 2002 | 50 | 0.040 |
Why?
| | Labor, Obstetric | 1 | 2002 | 66 | 0.040 |
Why?
| | Reference Values | 3 | 2009 | 797 | 0.040 |
Why?
| | Pyrimidines | 1 | 2005 | 532 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-sis | 1 | 2001 | 39 | 0.040 |
Why?
| | Pancreas | 2 | 2018 | 341 | 0.040 |
Why?
| | Administration, Topical | 1 | 2001 | 150 | 0.040 |
Why?
| | Venoms | 1 | 2020 | 22 | 0.040 |
Why?
| | Algorithms | 1 | 2008 | 1837 | 0.040 |
Why?
| | DNA | 4 | 1994 | 1463 | 0.040 |
Why?
| | Vitamin D | 1 | 2004 | 400 | 0.040 |
Why?
| | Rats, Inbred BB | 2 | 1991 | 5 | 0.040 |
Why?
| | Kinetics | 4 | 1994 | 1627 | 0.040 |
Why?
| | Diagnostic Techniques, Endocrine | 1 | 2020 | 14 | 0.040 |
Why?
| | HLA-DR2 Antigen | 1 | 1999 | 8 | 0.040 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2019 | 76 | 0.040 |
Why?
| | Antibodies, Heterophile | 1 | 1999 | 13 | 0.040 |
Why?
| | Bacterial Proteins | 2 | 2018 | 955 | 0.040 |
Why?
| | Membrane Proteins | 2 | 2004 | 1166 | 0.040 |
Why?
| | Pregnancy Outcome | 1 | 2003 | 476 | 0.040 |
Why?
| | Lymphocytes | 1 | 2002 | 382 | 0.040 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 3 | 2007 | 44 | 0.040 |
Why?
| | Interleukin-7 | 1 | 2019 | 65 | 0.040 |
Why?
| | HLA-DRB1 Chains | 3 | 2009 | 109 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2023 | 732 | 0.040 |
Why?
| | Pseudomonas | 2 | 1990 | 33 | 0.040 |
Why?
| | HLA-A Antigens | 2 | 2011 | 52 | 0.040 |
Why?
| | Mice, Inbred BALB C | 4 | 2011 | 1253 | 0.040 |
Why?
| | CD4-CD8 Ratio | 1 | 2019 | 23 | 0.040 |
Why?
| | ROC Curve | 1 | 2021 | 614 | 0.040 |
Why?
| | Lymphopenia | 1 | 2019 | 65 | 0.040 |
Why?
| | Hemorrhage | 1 | 1984 | 809 | 0.040 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2022 | 549 | 0.040 |
Why?
| | Leg | 1 | 2001 | 239 | 0.040 |
Why?
| | Methylation | 1 | 2019 | 242 | 0.040 |
Why?
| | Postpartum Period | 1 | 2002 | 365 | 0.040 |
Why?
| | Databases, Factual | 1 | 2004 | 1486 | 0.040 |
Why?
| | Meals | 1 | 2020 | 130 | 0.030 |
Why?
| | Insulin Lispro | 3 | 2004 | 42 | 0.030 |
Why?
| | Seroconversion | 1 | 2018 | 49 | 0.030 |
Why?
| | Mucosal-Associated Invariant T Cells | 1 | 2018 | 37 | 0.030 |
Why?
| | Therapies, Investigational | 1 | 2018 | 18 | 0.030 |
Why?
| | Macrophages | 2 | 1983 | 1511 | 0.030 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2018 | 13 | 0.030 |
Why?
| | B7-2 Antigen | 1 | 2017 | 27 | 0.030 |
Why?
| | Seroepidemiologic Studies | 1 | 2018 | 172 | 0.030 |
Why?
| | Wound Healing | 1 | 2001 | 351 | 0.030 |
Why?
| | Ikaros Transcription Factor | 1 | 2018 | 23 | 0.030 |
Why?
| | Colorado | 2 | 2024 | 4564 | 0.030 |
Why?
| | Glucose | 1 | 2023 | 1047 | 0.030 |
Why?
| | Cell Death | 1 | 2019 | 383 | 0.030 |
Why?
| | Twins | 1 | 2018 | 156 | 0.030 |
Why?
| | Mice, Transgenic | 2 | 2018 | 2182 | 0.030 |
Why?
| | Rats | 3 | 1991 | 5597 | 0.030 |
Why?
| | Drug Discovery | 1 | 2018 | 155 | 0.030 |
Why?
| | Genetic Markers | 1 | 1998 | 331 | 0.030 |
Why?
| | Clone Cells | 3 | 2004 | 266 | 0.030 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2016 | 27 | 0.030 |
Why?
| | Structure-Activity Relationship | 2 | 2011 | 570 | 0.030 |
Why?
| | Patient Care Planning | 1 | 2018 | 169 | 0.030 |
Why?
| | Gene Expression Regulation | 3 | 2014 | 2608 | 0.030 |
Why?
| | CD56 Antigen | 1 | 2016 | 35 | 0.030 |
Why?
| | Luminescent Measurements | 1 | 2017 | 76 | 0.030 |
Why?
| | Antigens, CD | 2 | 2014 | 555 | 0.030 |
Why?
| | Environment | 1 | 2018 | 305 | 0.030 |
Why?
| | HLA-DQ beta-Chains | 2 | 2009 | 57 | 0.030 |
Why?
| | Influenza A virus | 1 | 1997 | 113 | 0.030 |
Why?
| | Receptors, IgG | 1 | 2016 | 76 | 0.030 |
Why?
| | Leukocyte Common Antigens | 2 | 2007 | 88 | 0.030 |
Why?
| | United States | 4 | 2015 | 15966 | 0.030 |
Why?
| | Cell Count | 1 | 2017 | 320 | 0.030 |
Why?
| | Somalia | 1 | 2016 | 7 | 0.030 |
Why?
| | Antibody Specificity | 2 | 2007 | 181 | 0.030 |
Why?
| | Isoindoles | 1 | 1995 | 5 | 0.030 |
Why?
| | Forecasting | 1 | 1998 | 391 | 0.030 |
Why?
| | Parasitemia | 1 | 1995 | 15 | 0.030 |
Why?
| | Orphan Drug Production | 1 | 2015 | 5 | 0.030 |
Why?
| | Predictive Value of Tests | 2 | 2012 | 2115 | 0.030 |
Why?
| | Organ Specificity | 2 | 2007 | 312 | 0.030 |
Why?
| | Radiation-Sensitizing Agents | 1 | 1995 | 43 | 0.030 |
Why?
| | Coloring Agents | 1 | 1995 | 93 | 0.030 |
Why?
| | Minnesota | 1 | 2016 | 169 | 0.030 |
Why?
| | Cities | 1 | 2016 | 143 | 0.030 |
Why?
| | Cohort Studies | 3 | 2015 | 5960 | 0.030 |
Why?
| | Transfusion Reaction | 1 | 1995 | 63 | 0.030 |
Why?
| | Chagas Disease | 1 | 1995 | 42 | 0.030 |
Why?
| | Intestines | 1 | 2018 | 358 | 0.030 |
Why?
| | Immunity, Humoral | 1 | 2016 | 120 | 0.030 |
Why?
| | Ethics, Medical | 1 | 2015 | 87 | 0.030 |
Why?
| | Immunity, Active | 1 | 2014 | 8 | 0.030 |
Why?
| | Early Diagnosis | 1 | 2015 | 249 | 0.030 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2015 | 396 | 0.030 |
Why?
| | Immunoglobulins | 1 | 2014 | 160 | 0.030 |
Why?
| | Immunity, Innate | 2 | 2009 | 846 | 0.030 |
Why?
| | Opportunistic Infections | 1 | 2014 | 45 | 0.030 |
Why?
| | Proline | 1 | 1994 | 83 | 0.030 |
Why?
| | Transcription, Genetic | 4 | 1994 | 1496 | 0.030 |
Why?
| | Single-Blind Method | 1 | 2014 | 312 | 0.030 |
Why?
| | Immunoglobulin Idiotypes | 1 | 1993 | 28 | 0.030 |
Why?
| | Transplantation, Autologous | 1 | 2015 | 290 | 0.030 |
Why?
| | In Vitro Techniques | 1 | 1995 | 1047 | 0.030 |
Why?
| | Protein Structure, Secondary | 1 | 1994 | 369 | 0.030 |
Why?
| | Sequence Deletion | 1 | 1994 | 193 | 0.020 |
Why?
| | Drug Combinations | 1 | 2014 | 390 | 0.020 |
Why?
| | Europe | 1 | 2014 | 412 | 0.020 |
Why?
| | Prosthesis Design | 1 | 2015 | 357 | 0.020 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2013 | 37 | 0.020 |
Why?
| | Interleukin-10 | 1 | 2015 | 309 | 0.020 |
Why?
| | Mutagenesis | 1 | 1994 | 192 | 0.020 |
Why?
| | Polymerase Chain Reaction | 3 | 2009 | 1054 | 0.020 |
Why?
| | Cost of Illness | 1 | 2015 | 321 | 0.020 |
Why?
| | Formamides | 1 | 1992 | 8 | 0.020 |
Why?
| | Herpesviridae | 1 | 2012 | 22 | 0.020 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2015 | 558 | 0.020 |
Why?
| | Immunocompromised Host | 1 | 2014 | 201 | 0.020 |
Why?
| | Virus Replication | 3 | 1997 | 529 | 0.020 |
Why?
| | Escherichia coli Proteins | 1 | 1994 | 206 | 0.020 |
Why?
| | Body Mass Index | 1 | 2021 | 2438 | 0.020 |
Why?
| | Influenza Vaccines | 1 | 1997 | 529 | 0.020 |
Why?
| | Interleukins | 1 | 2014 | 248 | 0.020 |
Why?
| | Mice, Inbred Strains | 2 | 1993 | 397 | 0.020 |
Why?
| | Renin | 1 | 2012 | 34 | 0.020 |
Why?
| | Graft Survival | 1 | 2015 | 526 | 0.020 |
Why?
| | Postprandial Period | 1 | 2013 | 118 | 0.020 |
Why?
| | Pregnancy | 2 | 2003 | 7190 | 0.020 |
Why?
| | RNA, Antisense | 1 | 1992 | 18 | 0.020 |
Why?
| | Lymph Nodes | 2 | 2006 | 502 | 0.020 |
Why?
| | Virus Activation | 1 | 2012 | 95 | 0.020 |
Why?
| | Ligands | 2 | 2005 | 673 | 0.020 |
Why?
| | Indoles | 1 | 1995 | 501 | 0.020 |
Why?
| | HLA-B15 Antigen | 1 | 2011 | 11 | 0.020 |
Why?
| | Sample Size | 1 | 2011 | 123 | 0.020 |
Why?
| | Phagocytosis | 2 | 1983 | 299 | 0.020 |
Why?
| | Proteomics | 1 | 2018 | 1195 | 0.020 |
Why?
| | Cognition Disorders | 1 | 2015 | 538 | 0.020 |
Why?
| | Thallium Radioisotopes | 1 | 1991 | 8 | 0.020 |
Why?
| | Societies, Medical | 1 | 2015 | 887 | 0.020 |
Why?
| | Receptors, Cell Surface | 2 | 1983 | 377 | 0.020 |
Why?
| | Viral Core Proteins | 1 | 1990 | 22 | 0.020 |
Why?
| | Vitamin D-Binding Protein | 1 | 2010 | 15 | 0.020 |
Why?
| | RNA Splicing | 1 | 1992 | 284 | 0.020 |
Why?
| | Chronic Disease | 1 | 2017 | 1813 | 0.020 |
Why?
| | HLA-B8 Antigen | 1 | 2010 | 11 | 0.020 |
Why?
| | Small Molecule Libraries | 1 | 2011 | 111 | 0.020 |
Why?
| | Receptors, Calcitriol | 1 | 2010 | 55 | 0.020 |
Why?
| | Isoantigens | 1 | 1990 | 17 | 0.020 |
Why?
| | Amino Acid Substitution | 2 | 2002 | 304 | 0.020 |
Why?
| | Rats, Inbred Strains | 1 | 1990 | 321 | 0.020 |
Why?
| | Spleen | 3 | 2002 | 508 | 0.020 |
Why?
| | Linkage Disequilibrium | 1 | 2010 | 246 | 0.020 |
Why?
| | RNA Viruses | 1 | 1990 | 76 | 0.020 |
Why?
| | Chemokines | 1 | 2010 | 218 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2010 | 406 | 0.020 |
Why?
| | Homozygote | 1 | 2009 | 199 | 0.020 |
Why?
| | Pedigree | 1 | 2010 | 514 | 0.020 |
Why?
| | Immunoblotting | 1 | 2009 | 300 | 0.020 |
Why?
| | Transplantation, Homologous | 1 | 1990 | 415 | 0.020 |
Why?
| | Coculture Techniques | 1 | 2009 | 246 | 0.020 |
Why?
| | Nausea | 1 | 2009 | 111 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2016 | 2947 | 0.020 |
Why?
| | Logistic Models | 1 | 2014 | 2117 | 0.020 |
Why?
| | Vomiting | 1 | 2009 | 130 | 0.020 |
Why?
| | Interferon-alpha | 1 | 2009 | 197 | 0.020 |
Why?
| | Immunoglobulin M | 1 | 2009 | 284 | 0.020 |
Why?
| | Coronary Disease | 1 | 1991 | 383 | 0.020 |
Why?
| | Genetic Complementation Test | 1 | 1988 | 66 | 0.020 |
Why?
| | Genetic Vectors | 1 | 2009 | 337 | 0.020 |
Why?
| | Cell Line | 2 | 2004 | 2882 | 0.020 |
Why?
| | Codon | 1 | 1988 | 94 | 0.020 |
Why?
| | DNA Methylation | 1 | 2013 | 681 | 0.020 |
Why?
| | Exercise Test | 1 | 1991 | 634 | 0.020 |
Why?
| | Fever | 1 | 2009 | 311 | 0.020 |
Why?
| | Immunotherapy, Adoptive | 1 | 1991 | 337 | 0.020 |
Why?
| | Up-Regulation | 1 | 2010 | 851 | 0.020 |
Why?
| | Life Style | 1 | 1990 | 479 | 0.020 |
Why?
| | Microscopy, Electron | 1 | 1988 | 415 | 0.020 |
Why?
| | DNA-Binding Proteins | 1 | 1994 | 1499 | 0.020 |
Why?
| | Antisocial Personality Disorder | 1 | 1988 | 121 | 0.020 |
Why?
| | Gastrointestinal Diseases | 1 | 2009 | 216 | 0.020 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2007 | 80 | 0.020 |
Why?
| | Morphogenesis | 1 | 1988 | 173 | 0.020 |
Why?
| | Age Distribution | 1 | 2007 | 403 | 0.020 |
Why?
| | NF-kappa B | 1 | 2010 | 661 | 0.020 |
Why?
| | Models, Molecular | 1 | 2011 | 1618 | 0.020 |
Why?
| | Chromogranins | 1 | 2006 | 13 | 0.020 |
Why?
| | Social Environment | 1 | 1988 | 254 | 0.010 |
Why?
| | Phosphorylation | 1 | 2010 | 1732 | 0.010 |
Why?
| | Mice, Inbred C3H | 2 | 1983 | 251 | 0.010 |
Why?
| | Suicide, Attempted | 1 | 1990 | 422 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2007 | 758 | 0.010 |
Why?
| | Hemodynamics | 1 | 1991 | 1121 | 0.010 |
Why?
| | Psychotic Disorders | 1 | 1988 | 186 | 0.010 |
Why?
| | Chemokine CXCL11 | 1 | 2005 | 3 | 0.010 |
Why?
| | Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 2005 | 15 | 0.010 |
Why?
| | Keratins | 1 | 2006 | 172 | 0.010 |
Why?
| | Thyroglobulin | 1 | 2005 | 29 | 0.010 |
Why?
| | Alprostadil | 1 | 2005 | 29 | 0.010 |
Why?
| | Iodide Peroxidase | 1 | 2005 | 34 | 0.010 |
Why?
| | Chemokine CXCL9 | 1 | 2005 | 38 | 0.010 |
Why?
| | Glucagon | 1 | 2006 | 112 | 0.010 |
Why?
| | Chemokine CXCL10 | 1 | 2005 | 39 | 0.010 |
Why?
| | Mice, Inbred C57BL | 2 | 2011 | 5992 | 0.010 |
Why?
| | Lupus Coagulation Inhibitor | 1 | 1984 | 6 | 0.010 |
Why?
| | Fathers | 1 | 2005 | 51 | 0.010 |
Why?
| | Interpersonal Relations | 1 | 1988 | 400 | 0.010 |
Why?
| | Antigenic Variation | 1 | 2004 | 11 | 0.010 |
Why?
| | Dinoprostone | 1 | 2005 | 178 | 0.010 |
Why?
| | Mice, Inbred CBA | 1 | 2004 | 57 | 0.010 |
Why?
| | Tetanus Toxin | 1 | 2003 | 6 | 0.010 |
Why?
| | Infusion Pumps, Implantable | 1 | 2004 | 26 | 0.010 |
Why?
| | Chaperonin 60 | 1 | 2003 | 13 | 0.010 |
Why?
| | Insulin Aspart | 1 | 2004 | 30 | 0.010 |
Why?
| | Injections, Subcutaneous | 1 | 2004 | 164 | 0.010 |
Why?
| | Indicators and Reagents | 1 | 1983 | 106 | 0.010 |
Why?
| | Homeostasis | 1 | 2007 | 640 | 0.010 |
Why?
| | Fibrosis | 1 | 2006 | 548 | 0.010 |
Why?
| | Escherichia coli | 1 | 1988 | 854 | 0.010 |
Why?
| | Quality of Life | 1 | 2015 | 3185 | 0.010 |
Why?
| | Biological Assay | 1 | 1983 | 128 | 0.010 |
Why?
| | Fetal Macrosomia | 1 | 2003 | 62 | 0.010 |
Why?
| | Binding, Competitive | 1 | 1983 | 193 | 0.010 |
Why?
| | Interleukin-2 | 1 | 2004 | 437 | 0.010 |
Why?
| | C-Reactive Protein | 1 | 2005 | 416 | 0.010 |
Why?
| | Antigens, CD1d | 1 | 2002 | 68 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 2004 | 779 | 0.010 |
Why?
| | Models, Biological | 1 | 1990 | 1821 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2015 | 2919 | 0.010 |
Why?
| | Cell Division | 1 | 2004 | 766 | 0.010 |
Why?
| | Antigens, Differentiation | 1 | 2002 | 77 | 0.010 |
Why?
| | Congenital Abnormalities | 1 | 2003 | 104 | 0.010 |
Why?
| | Antigens, Surface | 1 | 2002 | 157 | 0.010 |
Why?
| | Insulin Resistance | 1 | 2010 | 1241 | 0.010 |
Why?
| | Albuminuria | 1 | 2003 | 190 | 0.010 |
Why?
| | Sex Factors | 1 | 1988 | 2112 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2006 | 1716 | 0.010 |
Why?
| | CTLA-4 Antigen | 1 | 2002 | 104 | 0.010 |
Why?
| | Celiac Disease | 1 | 2005 | 308 | 0.010 |
Why?
| | Temperature | 2 | 1997 | 679 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 2005 | 1539 | 0.010 |
Why?
| | Alcoholism | 1 | 1988 | 817 | 0.010 |
Why?
| | HLA-DQ alpha-Chains | 1 | 1999 | 16 | 0.010 |
Why?
| | Birth Weight | 1 | 2003 | 522 | 0.010 |
Why?
| | Glutamine | 1 | 2000 | 109 | 0.010 |
Why?
| | Gestational Age | 1 | 2003 | 975 | 0.010 |
Why?
| | DNA-Directed RNA Polymerases | 2 | 1990 | 63 | 0.010 |
Why?
| | Alanine | 1 | 2000 | 171 | 0.010 |
Why?
| | Substance-Related Disorders | 1 | 1988 | 1094 | 0.010 |
Why?
| | Mothers | 1 | 2005 | 775 | 0.010 |
Why?
| | Aging | 2 | 2007 | 1966 | 0.010 |
Why?
| | Incidence | 1 | 2005 | 2879 | 0.010 |
Why?
| | Mesocricetus | 1 | 1997 | 46 | 0.010 |
Why?
| | Cricetinae | 1 | 1997 | 303 | 0.010 |
Why?
| | Chickens | 1 | 1997 | 191 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2005 | 3540 | 0.010 |
Why?
| | Vaccines, Attenuated | 1 | 1997 | 129 | 0.010 |
Why?
| | Trifluoroethanol | 1 | 1994 | 1 | 0.010 |
Why?
| | Polydeoxyribonucleotides | 1 | 1994 | 14 | 0.010 |
Why?
| | Transfection | 1 | 1997 | 940 | 0.010 |
Why?
| | Electrophoresis, Agar Gel | 1 | 1994 | 25 | 0.010 |
Why?
| | Sodium Dodecyl Sulfate | 1 | 1994 | 26 | 0.010 |
Why?
| | Survival Rate | 1 | 1999 | 2089 | 0.010 |
Why?
| | Circular Dichroism | 1 | 1994 | 150 | 0.010 |
Why?
| | p-Azobenzenearsonate | 1 | 1993 | 5 | 0.010 |
Why?
| | Genes, Immunoglobulin | 1 | 1993 | 29 | 0.010 |
Why?
| | Immunoglobulin kappa-Chains | 1 | 1993 | 23 | 0.010 |
Why?
| | DNA, Single-Stranded | 1 | 1994 | 119 | 0.010 |
Why?
| | Immunoglobulin Variable Region | 1 | 1993 | 80 | 0.010 |
Why?
| | Cross Reactions | 1 | 1993 | 130 | 0.010 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 1993 | 85 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1992 | 331 | 0.010 |
Why?
| | Restriction Mapping | 1 | 1990 | 80 | 0.010 |
Why?
| | Radionuclide Imaging | 1 | 1991 | 112 | 0.010 |
Why?
| | Computer Simulation | 1 | 1994 | 1025 | 0.000 |
Why?
| | Genome, Viral | 1 | 1992 | 218 | 0.000 |
Why?
| | Neoplasms | 1 | 1983 | 2875 | 0.000 |
Why?
| | Lethal Dose 50 | 1 | 1983 | 15 | 0.000 |
Why?
| | Fibrosarcoma | 1 | 1983 | 23 | 0.000 |
Why?
| | Leukocytosis | 1 | 1983 | 32 | 0.000 |
Why?
| | Neoplasm Transplantation | 1 | 1983 | 251 | 0.000 |
Why?
| | Leukocyte Count | 1 | 1983 | 316 | 0.000 |
Why?
| | Hypertension | 1 | 1991 | 1263 | 0.000 |
Why?
| | Dogs | 1 | 1983 | 437 | 0.000 |
Why?
|
|
Gottlieb's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|